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Introduction
Transcatheter aortic valve replacement (TAVR) has become
the preferred treatment option for high-risk surgical patients
with severe symptomatic aortic stenosis.
In the PARTNER study, major safety concerns have been
raised about the neurological outcome following TAVR.1
A large meta-analysis over 1,618 TAVR patients showed a
30-day stroke rate of 6.9%.2 Indeed, the population that
develops neurological events tends to have a higher mortal-
ity rate. The principal cause of the neurological events is
considered to be the detachment of aortic debris during
catheter manipulation of the calciﬁed valve as well as
cerebral embolization during retrograde aortic arch passage
of the device.
Furthermore, a signiﬁcant supra-aortic disease is fre-
quently associated with the valvular lesion. Preoperative
assessment must be addressed tominimize the risk of stroke
due to supra-aortic trunks disease.
Case
An 84-year-old Caucasian man was referred for severe symp-
tomatic aortic stenosis. He had a history of hard smoke,
coronary artery disease, arterial hypertension, type II diabetes
mellitus, chronic renal failure, permanent atrial ﬁbrillation,
and a previous right carotid artery stenting. The main symp-
toms were rest dyspnea and recurrent transient right-side
paresthesia and weakness.
The transthoracic echocardiogram showed a low-gradi-
ent–low-ﬂowsevere aortic stenosis associatedwith ischemic
dilated cardiomyopathy (ejection fraction of 40%). An ultra-
sound scan of the supra-aortic trunks showed patency of the
right carotid stent and the presence of severe contralateral
carotid stenosis.
The severity of the stenosis (>80%) according to the North
American Symptomatic Carotid Endarterectomy Trial (NAS-
CET) criteria was conﬁrmed by a cervical computed tomo-
graphy scan; the scan also documented several old bilateral
ischemic cerebral lesions.
In consideration of the high surgical risk with a “Society of
Thoracic Surgeon” risk score of morbidity or mortality of
32%, we planned a transcatheter approach.
The key question was: Is it safe to perform carotid stenting
before TAVR? After Heart Team discussion, we planned a
combined transcatheter procedure. Because of the common
developmentofbradycardia andhypotensionaftercarotid stent-
ing and raised risk of asystole in a patient having small aortic
oriﬁce area, we performed the aortic valve replacement ﬁrst.
Heparin was given to achieve a target activating clotting
time of 200 seconds. By means of a 14-Fr sheath we im-
planted via a transfemoral access a 23-mm Edwards SAPIEN
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Abstract No consensus exists on the timing, safety, and efﬁcacy of treating severe symptomatic
aortic and carotid stenosis. In the older population and in the presence of multiple
comorbidities that arise during the surgery, a less invasive transcatheter treatmentmay
be the only reasonable option. We discuss this topic by analyzing a case of an 84-year-
old man who underwent a combined single-stage transcatheter procedure.
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S3 bioprosthesis (Edwards Lifesciences; Irvine, California,
United States; ►Fig. 1).
After hemodynamic normalization, we implanted a
7  40 mm Carotid WALLSTENT (Boston Scientiﬁc; Massa-
chussets, United States) in the left carotid artery (►Fig. 2).
The brain was protected by a 3.2-Fr FilterWire EZ (Boston
Scientiﬁc) device. The postoperative recovery was unevent-
ful. He is alive and well at 2 years of follow-up.
Discussion
Currently, there is no consensus on the timing, safety, and
efﬁcacy of treating concomitant severe symptomatic aortic
and carotid stenosis. Nowadays, in the older population and
in those having multiple comorbidities, a transcatheter
approach is an attractive option.
Owing to the poor prognosis of these untreated condi-
tions, any effort must be achieved to plan the best treatment
in the setting of the multidisciplinary team.
Some authors claim to treat the carotid lesion ﬁrst, gen-
erally 1 month before the TAVR.3 The common thought is that
the embolic risk is predominantly due to the intrinsic pre-
existing carotid disease rather than the aortic manipulation.
By contrast, it is known that stroke rate in asymptomatic
patients with a carotid stenosis of more than 80% range from
3.5 to 5%.4
Fig. 1 (A and B) Fluoroscopic image of the delivery of the bioprosthesis. (C and D) Intraoperative transesophageal images demonstrating the
good result of the implantation.
Fig. 2 Angiographic images of the left carotid axis before (A, yellow arrow) and after (B, red arrow) the stenting.
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In these situations, the clinical dilemma is that if we address
the valveﬁrst,most of the neurological risks still exist due to the
embolization of debris from the aortic arch as well as from the
valve and from the diseased carotid artery, especially without
protection device. On the other hand, the risk of hemodynamic
depression during ballooning and deployment of the valvewith
an impaired cerebral perfusion on the brain side of the severe
stenosis may further increase the procedural risk.
We decided to perform a single combined transcatheter
procedure to simultaneously treat both conditions in a unique
intervention.Weperformedﬁrst the TAVRbecausewe assumed
the patient to be at a high risk of hemodynamic instability. And
wedecided to simultaneously treatbothpathological conditions
to manage the symptomatic situations in a one-stage fashion.
We still need a broader long-term study on this cohort of
patients to effectively evaluate the feasibility and security of
this single-stage procedure.
Conﬂict of Interest
None.
Funding
None.
References
1 Beohar N, Kirtane AJ, Blackstone E, et al. Trends in complications
and outcomes of patients undergoing transfemoral transcath-
eter aortic valve replacement: experience from the partner
continued access registry. JACC Cardiovasc Interv 2016;9(04):
355–363
2 KondurA, BriasoulisA, PallaM, et al.Meta-Analysis of Transcatheter
AorticValveReplacementVersusSurgicalAorticValveReplacement
inPatientsWithSevereAorticValve Stenosis.AmJCardiol 2016;117
(02):252–257
3 Ravindra VM, Mazur MD, Kumpati GS, et al. Carotid Artery
Stenosis in the Setting of Transcatheter Aortic Valve Replacement:
Clinical and Technical Considerations of Carotid Stenting. World
Neurosurg 2016;86:194–198
4 Thourani VH, Gunter RL, Neravetla S, et al. Use of transaortic,
transapical, and transcarotid transcatheter aortic valve replace-
ment in inoperable patients. Ann Thorac Surg 2013;96(04):
1349–1357
Thoracic and Cardiovascular Surgeon Reports Vol. 6 No. 1/2017
TAVR and Carotid Stenting Gennari et al. e39
